Collplant Biotechnologies Ltd Cash Flow Conversion Efficiency
Collplant Biotechnologies Ltd cash flow conversion efficiency. Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has a cash flow conversion efficiency ratio of -0.309x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Collplant Biotechnologies Ltd (2012–2024)
Cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. This chart illustrates how Collplant Biotechnologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Collplant Biotechnologies Ltd stock price for real-time trading data and today's change.
Collplant Biotechnologies Ltd Cash Flow Conversion Ratio Explained
Collplant Biotechnologies Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Collplant Biotechnologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their cash flow conversion efficiency. Also see how much is Collplant Biotechnologies Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dovre Group Plc
HE:DOV1V
|
-0.559x |
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
-0.817x |
|
Lite Access Technologies Inc
V:LTE
|
1.235x |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
0.083x |
|
Coloured Ties Capital Inc
V:TIE
|
-0.031x |
|
SG COMPANY S.P.A.
F:7KZ
|
N/A |
|
Nexted Group Ltd
AU:NXD
|
0.510x |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. Review Collplant Biotechnologies Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-14.09 Million | -1.047x | -973.53% |
| 2023-12-31 | $28.34 Million | $-2.76 Million | -0.097x | +77.02% |
| 2022-12-31 | $32.28 Million | $-13.70 Million | -0.424x | -865.55% |
| 2021-12-31 | $45.12 Million | $2.50 Million | 0.055x | +105.58% |
| 2020-12-31 | $4.48 Million | $-4.45 Million | -0.994x | +28.73% |
| 2019-12-31 | $4.09 Million | $-5.70 Million | -1.395x | -445.61% |
| 2018-12-31 | $4.76 Million | $-1.22 Million | -0.256x | +86.54% |
| 2017-12-31 | $2.61 Million | $-4.97 Million | -1.900x | +49.26% |
| 2016-12-31 | $1.34 Million | $-5.02 Million | -3.745x | -152.18% |
| 2015-12-31 | $2.51 Million | $-3.72 Million | -1.485x | -64.13% |
| 2014-12-31 | $3.68 Million | $-3.33 Million | -0.905x | -84.26% |
| 2013-12-31 | $7.78 Million | $-3.82 Million | -0.491x | +46.58% |
| 2012-12-31 | $4.20 Million | $-3.86 Million | -0.919x | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more